21:47 , Dec 1, 2017 |  BC Week In Review  |  Financial News

Catalyst raises $50M in follow-on

On Nov. 28, neurological disease company Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) raised $50 million through the sale of 14.3 million shares at $3.50 in a follow-on underwritten by Piper Jaffray, SunTrust Robinson, H.C. Wainwright and Roth...
21:49 , Nov 28, 2017 |  BC Extra  |  Financial News

Catalyst raises $50M in follow-on

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) gained $0.37 (10%) to $3.98 Tuesday after raising $50 million through the sale of 14.3 million shares at $3.50 in a follow-on underwritten by Piper Jaffray, SunTrust Robinson, H.C. Wainwright and...
13:02 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Firdapse: Ph II/III data

Top-line data from a double-blind, crossover, Italian Phase II/III trial in 7 MUSK-MG patients showed that dose-titrated Firdapse met the co-primary endpoints of improving QMG and MG-ADL total scores from baseline to day 7 vs....
13:02 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Firdapse: Ph II/III data

Top-line data from a double-blind, crossover, Italian Phase II/III trial in 7 MUSK-MG patients showed that dose-titrated Firdapse met the co-primary endpoints of improving QMG and MG-ADL total scores from baseline to day 7 vs....
17:05 , Mar 15, 2017 |  BC Extra  |  Clinical News

Catalyst climbs on Firdapse readout in rare form of MG

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) jumped $0.38 (32%) to $1.55 on Wednesday after it said Firdapse amifampridine phosphate met the co-primary endpoints in a Phase II/III trial to treat myasthenia gravis in patients with anti-muscle associated...
08:00 , Feb 29, 2016 |  BioCentury  |  Regulation

Competitive consequences

Whatever the reason FDA refused to file an NDA for Catalyst Pharmaceuticals Inc.'s Firdapse amifampridine, the delay could allow a competitor with a less expensive form of the molecule to gain ground in a race...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Firdapse amifampridine: Clinical trial started

Catalyst said investigators began a double-blind, placebo-controlled, crossover, Italian clinical trial to evaluate up to 25 mg Firdapse given 3-4 times daily in about 20 patients. Firdapse is approved in the EU for the symptomatic...
08:00 , Dec 16, 1996 |  BioCentury  |  Strategy

Regeneron's P & G deal

Although Procter & Gamble Co. isn't the most obvious partner for the biotech industry, the consumer products company is teaming up with Regeneron Pharmaceuticals Inc. (REGN) to develop therapeutics for muscle diseases and disorders. The...
07:00 , May 20, 1996 |  BC Week In Review  |  Company News

Regeneron other research news

REGN researchers and colleagues have elucidated a portion of the communication system between nerves and muscles, which should aid in the study of the muscle deterioration that accompanies muscular dystrophies, motor neuron disease and myasthenia...